Results 21 to 30 of about 13,230 (236)

The novel ortho-chloro derivate propafenone induced relaxation in isolated rat aorta [PDF]

Acta Veterinaria, 2013
The information on the inhibitory effect of propafenone in vascular smooth muscle is sparse. Propafenone acts through blockage of voltage-dependent cardiac Na+ channels, L-type Ca2+ channels, voltage-sensitive K+ (Kv) channels, as well as β-adrenergic
Ivković Branka, Gojković-Bukarica Ljiljana, Vladimirov S., Radmila Novaković, Ćupić V., Lešić A., Bumbaširević M., Šćepanović R.   +7 more
doaj   +1 more source

ANTIARRHYTHMIC EFFICACY OF PROPAFENONE IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2016
Aim. To assess propafenone antiarrhythmic efficacy and optimal timing of the drug administration for relief of persistent atrial fibrillation (PAF). Material and methods.
R. D. Kurbanov, N. U. Zakirov, Sh. K. Azizov   +2 more
doaj   +3 more sources

Revisiting propafenone toxicity [PDF]

BMJ Case Reports, 2017
Ali A. Alsaad, Yahaira Ortiz González, Christopher Austin, Fred Kusumoto   +3 more
openalex   +2 more sources

A Mechanistic Clinical Trial Using (R)- Versus (S)-Propafenone to Test RyR2 (Ryanodine Receptor) Inhibition for the Prevention of Atrial Fibrillation Induction

Circulation: Arrhythmia and Electrophysiology, 2022
Background: Experimental data suggest ryanodine receptor-mediated intracellular calcium leak is a mechanism for atrial fibrillation (AF), but evidence in humans is still needed.
M. B. Shoemaker, Z. Yoneda, Diane M. Crawford, W. S. Akers, T. Richardson, Jay A. Montgomery, Sharon Phillips, Y. Shyr, Pablo J. Saavedra, J. Estrada, Arvindh N. Kanagasundram, S. Shen, G. Michaud, G. Crossley, Christopher R. Ellis, B. Knollmann   +15 more
semanticscholar   +1 more source

Monitoring Serum Bisoprolol Concentrations in Patients With Heart Failure With Reduced Ejection Fraction: Results of a Pilot Study From Routine Health Care. [PDF]

Pharmacol Res Perspect
ABSTRACT Bisoprolol is a second‐generation, highly selective beta‐1 adrenergic receptor antagonist with various beneficial effects in patients with heart failure. Interindividual variability in response to bisoprolol is known, and finding the optimal dose for individual patients with heart failure is still challenging.
Kacirova I, Lazarova M, Urinovska R, Dodulik J, Drienikova D, Vaclavik J.   +5 more
europepmc   +2 more sources

Experience of using propafenone in newborns and young children with arrhythmias

Российский кардиологический журнал, 2020
Aim. To evaluate the efficacy and safety of propafenone therapy in newborns and young children, including children with congenital heart defects (CHD).Material and methods.
T. K. Kruchina, T. S. Kovalchuk, E. S. Vasichkina, B. A. Tatarsky   +3 more
doaj   +1 more source

Propafenone Poisoning of a Female Adolescent After a Suicide Attempt

Cureus, 2021
Propafenone is an antiarrhythmic agent for the management of ventricular and supraventricular tachycardia and atrial fibrillation. Propafenone poisoning is rare but may be life-threatening due to drug-induced arrhythmias.
S. Keramari, A. Poutoglidis, F. Poutoglidou, G. Kaiafa, Michael Keramaris   +4 more
semanticscholar   +1 more source

Antiarrhythmic effects of newly developed propafenone derivatives [PDF]

Arhiv za farmaciju, 2022
It is well known that the presence of different chemical groups in drug molecules influences their pharmacological properties. The aim of our study is to investigate whether newly synthesized derivatives of propafenone, with changes in benzyl moiety ...
Ivković Branka, Opačić Dragan, Džudović Boris, Crevar Milkica, Gojković-Bukarica Ljiljana   +4 more
doaj   +1 more source

Formulation and stability of an extemporaneously compounded propafenone hydrochloride oral suspension for children with arrhythmia

European Journal of Hospital Pharmacy: Science and Practice, 2021
Objectives In children, supraventricular tachycardia is the most common form of arrhythmia, and propafenone is an effective class Ic antiarrhythmic agent used in this population.
Yi-Shiu Lin, Shu-Chiao Lin, Ya-Ting Hsieh, Ling-Yu Liu, Chiu-Hsin Lin, Li-Jiuan Shen, Chih-Fen Huang   +6 more
semanticscholar   +1 more source

Structural Insights into Differences in Drug-binding Selectivity between Two Forms of Human α1-Acid Glycoprotein Genetic Variants, the A and F1*S Forms [PDF]

, 2011
Human α1-acid glycoprotein (hAGP) in serum functions as a carrier of basic drugs. In most individuals, hAGP exists as a mixture of two genetic variants, the F1*S and A variants, which bind drugs with different selectivities. We prepared a mutant of the A
Curry, S, Fukunaga, N, Izumi, M, Maruyama, T, Nakamura, T, Nishi, K, Ono, T, Otagiri, M, Suenaga, A, Watanabe, H, Yamagata, Y   +10 more
core   +2 more sources